COMPOSITIONS AND METHODS FOR INHIBITING GSK3 ACTIVITY AND USES THEREOF
First Claim
Patent Images
1. An isolated nucleic acid comprising a sequence at least 95% identical to SEQ ID NO:
- 1 or a fragment thereof at least 24 residues in length, wherein the sequence encodes a polypeptide that binds adenylyl cyclase.
5 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are compositions and methods relating to peptides. The peptides can inhibit amyloid beta (Aβ) generation and reduce GSK-3 activities. Further provided are compositions and methods for treating or preventing, for example, Alzheimer'"'"'s disease, cancer, and diabetes.
-
Citations
57 Claims
-
1. An isolated nucleic acid comprising a sequence at least 95% identical to SEQ ID NO:
- 1 or a fragment thereof at least 24 residues in length, wherein the sequence encodes a polypeptide that binds adenylyl cyclase.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
13. A purified polypeptide, comprising an amino acid sequence at least 95% identical to the sequence SEQ ID NO:
- 2, or a fragment thereof at least 8 residues in length, wherein the polypeptide binds adenylyl cyclase.
- View Dependent Claims (14, 15)
-
16. A method of inhibiting GSK3 activity in a cell, comprising contacting the cell with an isolated nucleic acid comprising a sequence at least 95% identical to SEQ ID NO:
- 1 or a fragment thereof at least 24 residues in length, operably linked to an expression control sequence, wherein the sequence encodes a polypeptide that binds adenylyl cyclase.
- View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)
-
32. A method of inhibiting GSK3 activity in a cell, comprising contacting the cell with a purified polypeptide comprising an amino acid sequence at least 95% identical to the sequence SEQ ID NO:
- 2, or a fragment thereof at least 8 residues in length, wherein the polypeptide binds adenylyl cyclase.
- View Dependent Claims (33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)
-
45. A method of treating a subject with Alzheimer'"'"'s disease, cancer, or diabetes, the method comprising administering to the subject an expression vector encoding protein FG01, such that a therapeutically effective amount of protein FG01 is expressed in the subject.
- 46. A method of treating a subject with Alzheimer'"'"'s disease, cancer, or diabetes, the method comprising administering to the subject a cell comprising an expression vector encoding protein FG01, such that a therapeutically effective amount of protein FG01 is expressed by the cell in the subject.
-
49. A method comprising:
-
(a) contacting a purified polypeptide comprising an amino acid sequence at least 95% identical to the sequence SEQ ID NO;
2, or a fragment thereof at least 8 residues in length, wherein the polypeptide binds adenylyl cyclase, with a test compound; and(b) determining whether the test compound binds to the purified polypeptide, said binding being an indication that the test compound is a modulator of glycogen synthase kinase-3 (GSK-3). - View Dependent Claims (50, 51, 55)
-
-
52. A method of identifying a modulator of glycogen synthase kinase-3 (GSK-3), the method comprising:
-
(a) providing a cell comprising a nucleic acid encoding FG01 operably linked to an expression control sequence, wherein the nucleic acid comprises a sequence at least 95% identical to SEQ ID NO;
1, or a fragment thereof at least 24 residues in length, wherein the sequence encodes a polypeptide that binds adenylyl cyclase,(b) contacting the cell with a test compound; and (c) measuring expression of FG01, an increase or decrease in FG01 expression an indication that the compound is a modulator of GSK-3. - View Dependent Claims (53, 54, 56)
-
-
57. A method of identifying a compound that binds to FG01, the method comprising:
-
(a) providing a cell expressing FG01; (b) contacting the cell with a test compound; and (c) determining whether the test compound binds to FG01.
-
Specification